Overview

A Study of Bevacizumab (Avastin) in Participants With Newly Diagnosed Locally Advanced Rectal Cancer

Status:
Completed
Trial end date:
2016-03-23
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy and safety of two different neoadjuvant treatment approaches including bevacizumab in newly diagnosed participants with high risk locally advanced rectal cancer. Participants will be randomized into one of two treatment arms (Arm A or Arm B).
Phase:
Phase 2
Details
Lead Sponsor:
Hoffmann-La Roche
Treatments:
Bevacizumab
Fluorouracil
Folic Acid
Leucovorin
Levoleucovorin
Oxaliplatin